Search Results 101-110 of 17141 for ulcerative colitis

  1. Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) - Mayo Clinic

    Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) · Share · Facebook · Twitter.

  2. A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) - Mayo Clinic

    A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) · More about research at Mayo Clinic · Mayo ...

  3. A Study to Evaluate Effectiveness and Safety of TD-1473 in Ulcerative Colitis - Mayo Clinic

    ... ulcerative colitis with up to 60 weeks of treatment. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and ...

  4. A Study of the Long-Term Safety and Effectiveness of Adalimumab for Repeat Treatment of Pediatric Patients with Ulcerative Colitis - Mayo Clinic

    A Study of the Long-Term Safety and Effectiveness of Adalimumab for Repeat Treatment of Pediatric Patients with Ulcerative Colitis · Overview · Participation ...

  5. A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors - Mayo Clinic

    ... ulcerative colitis (UC) who are refractory to or intolerant of TNF inhibitors. Participation eligibility. Participant eligibility includes age, gender, type ...

  6. A Study to Evaluate the Safety, Effectiveness and Microbiological Response of Orally Administered ABI-M201 in Subjects with Mildly-to-Moderately Active Ulcerative Colitis with Ongoing Mesalamine Treatment - Mayo Clinic

    To evaluate a new oral treatment, ABI-M201 (or placebo) in individuals with mild to moderate Ulcerative Colitis who have sustained an inadequate response to ...

  7. Pharmacokinetics and Pharmacodynamic Biomarkers of Janus Kinase Inhibitor Therapy in Patients with Ulcerative Colitis (PROPHETIC Study) - Mayo Clinic

    Pharmacokinetics and Pharmacodynamic Biomarkers of Janus Kinase Inhibitor Therapy in Patients with Ulcerative Colitis (PROPHETIC Study) · Overview · Participation ...

  8. A Study to Assess the Effectiveness and Safety of Risankizumab in Subjects with Ulcerative Colitis - Mayo Clinic

    The purpose of this study is to evaluate safety and efficacy of risankizumab in subjects with ulcerative colitis (UC) in subjects who responded to induction ...

  9. Sulfasalazine (Oral Route) Proper Use - Mayo Clinic

    For treatment of ulcerative colitis: For oral dosage form (enteric-coated tablets):. Adults—At first, 500 to 1000 milligrams (mg) every 6 to 8 hours per day ...

  10. A Study to Evaluate the Patterns of Use of Biological Agents and Risk Factors for Discontinuation of Agents in Pediatric Crohn’s Disease (CD) and Ulcerative Colitis (UC) within the Pediatric Population - Mayo Clinic

    ... Ulcerative Colitis (UC) within the Pediatric Population. Print details. Share ... ulcerative colitis (UC) within the ICN network. This will be a ...